Capecitabine Dosing with Radiation in Pancreatic Cancer
For concurrent chemoradiation in pancreatic cancer, use capecitabine 825 mg/m² orally twice daily, Monday through Friday only (on radiation days), with standard fractionated radiation therapy (50.4 Gy in 28 fractions). This is the established phase II recommended dose with the best safety and tolerability profile 1.
Dosing Algorithm
Standard Concurrent Chemoradiation Regimen
- Capecitabine dose: 825 mg/m² PO BID
- Schedule: Monday-Friday only (days of radiation)
- Radiation: 50.4 Gy in 28 fractions over 5.5 weeks
- Duration: Throughout entire radiation course
This dosing was established through formal phase I dose-escalation studies where 1,000 mg/m² caused dose-limiting toxicities (grade 3 vomiting and fatigue), making 825 mg/m² the maximum tolerated dose 1.
Alternative Dosing Schedules (Context-Dependent)
Seven-days-per-week dosing (if preferred for logistical reasons):
- Capecitabine 675 mg/m² PO BID, given every day during radiation
- Combined with oxaliplatin 30 mg/m² weekly and 50.4 Gy radiation
- This was the MTD in the CORGI-U trial 2
Hypofractionated radiation approach:
- Capecitabine 1,000 mg/m² PO BID, Monday-Friday
- With 30 Gy in 10 fractions
- Used when adding vorinostat or other agents 3
Critical Dosing Considerations
Renal Function Adjustments (FDA Label)
This is mandatory and often overlooked:
- CrCl 30-50 mL/min: Reduce starting dose to 75% (approximately 620 mg/m² BID for the 825 mg/m² regimen) 4
- CrCl <30 mL/min: Contraindicated 4
- Patients with moderate renal impairment show 85% higher systemic exposure to toxic metabolites 4
Age Considerations
- A 20% increase in age results in 15% increase in AUC of toxic metabolite FBAL 4
- Elderly patients (>70 years) may require closer monitoring and dose adjustments
Food Administration
- Must be taken within 30 minutes after a meal 4
- Food reduces Cmax by 60% and AUC by 35%, which actually improves tolerability
- Taking on empty stomach increases toxicity risk
Toxicity Management
Most Common Toxicities with Concurrent Radiation
- Gastrointestinal: Nausea/vomiting (most common), diarrhea (dose-limiting at higher doses)
- Hematologic: Lymphopenia (76% incidence) 3
- Fatigue: Can be dose-limiting at 1,000 mg/m² 1
Dose Modification Strategy
When grade 3 toxicities occur:
- Hold capecitabine until toxicity resolves to grade ≤1
- Resume at 75% of previous dose (approximately 620 mg/m² BID)
- If grade 3 toxicity recurs, reduce to 50% of original dose (approximately 410 mg/m² BID)
Clinical Context and Efficacy
The 825 mg/m² Monday-Friday regimen with 50.4 Gy radiation achieved:
- 41.7% partial response rate
- 94.8% treatment completion rate
- Median overall survival 14.3 months in locally advanced disease 5
- Well-tolerated with only 21.6% grade 3 toxicities 5
Important caveat: The NCCN guidelines 6 discuss capecitabine primarily in the context of systemic chemotherapy combinations (gemcitabine plus capecitabine) rather than concurrent chemoradiation. The LAP07 study showed no overall survival benefit for adding chemoradiation versus continuing chemotherapy alone in locally advanced disease 7, which has tempered enthusiasm for chemoradiation. However, when chemoradiation is selected (particularly for consolidation after induction chemotherapy or in borderline resectable disease), the 825 mg/m² dose remains the evidence-based standard.
Warfarin Interaction Warning
Critical drug interaction: Capecitabine increases warfarin AUC by 57% and INR by 2.8-fold 4. Monitor INR closely and adjust warfarin dose accordingly if concurrent use is unavoidable.